In today's ACT Brief, we examine technology's real role in patient-site collaboration, why AI pilot failures stem from organization not innovation, and Novo's weight-loss drug results in competitive comparison.
|Articles|October 1, 2014
ACRP Expands Credentialing Program for Clinical Trial Investigators
ACRP announced changes to its investigator certification program
Advertisement
The Academy of Clinical Research Professionals announced changes to its investigator certification program that will allow for broader credentialing of principal investigators in clinical trials.
The Academy Board of Trustees voted to change the eligibility criteria for its Certified Physician Investigator (CPI) program to allow for individuals with a doctorate-level degree, such as PhD, Pharm.D, DNP, to earn recognition of their clinical research-specific expertise through certification. The CPI program had previously been open only to individuals holding an active medical license.
As part of its expansion of the CPI program's eligibility criteria, the Academy Board also approved a program title change from Certified Physician Investigator to Certified Principal Investigator.
Read the full release
Advertisement
Related to this article
Most AI pilots in drug development fail not from poor technology but from lack of strategic prioritization, organizational readiness, integrated data infrastructure, and disciplined governance, making success dependent on business discipline rather than technical capability.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It
2
Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development
3
DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites
4
How a Platform Approach Can Scale AI’s Impact in Life Sciences
5